Tom graduated University of Brighton with a BA (Hons) degree in Broadcast Journalism, leaving as the valedictorian of the class of 2015. His final year projects and dissertation were nominated for, and won, several awards, whilst he was also the Editor-in-Chief of the university’s news site during his time at Brighton. After previously writing for a property magazine, Tom joined the Proactive team in January 2016.
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
Consumers have been tightening their purse strings of late, but it seems we can still find the money to treat ourselves to a sausage roll or steak bake
Aldi sold almost £1bn worth of food and drink in the run-up to the holiday season, and Morrisons has responded by slashing the prices of more than 900 products
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult
Orphan drug status gives drugmakers certain benefits to encourage them to develop treatments for rare diseases which might otherwise lack sufficient profit motive
The AIM billionaire has bought two new drugs in the past six months, while it has also snapped up two companies
Ensifentrine was shown to be more effective than a placebo, although it didn’t improve patients’ breathing by as much as hoped
Secondary endpoints were confirmed last March and further analysis of the data has now found that the primary endpoint in symptom reduction was also met
The Stockpot column was inaugurated to act as a laboratory for investment ideas, and unlike a lot of lab experiments, hopefully things don't go horribly wrong
Of course if you’ve already done so, this article probably doesn’t apply to you…
Sometimes a cheap stock is cheap for a reason, not just because it’s good value…
The Rookie Investors has still got the Fever(tree), but would he have done had he set a stop-loss?